CoChat
Sign Up
Cited by 339Pharmacological Effects and Toxicity StudiesPregnancy and Medication ImpactEpilepsy research and treatment

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes

Open access
Veroniki, Areti Angeliki, Cogo, Elise, Rios, Patricia, Straus, Sharon E., Finkelstein, Yaron, Kealey, Ryan, Reynen, Emily, Soobiah, Charlene, Thavorn, Kednapa, Hutton, Brian, Hemmelgarn, Brenda R., Yazdi, Fatemeh, D’Souza, Jennifer, MacDonald, Heather, Tricco, Andrea C.·2017·BMC Medicine
DOI 10.1186/s12916-017-0845-1PMC PMC5418725
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Pregnant women with epilepsy frequently experience seizures related to pregnancy complications and are often prescribed anti-epileptic drugs (AEDs) to manage their symptoms. However, less is known about the comparative safety of AED exposure in utero. We aimed to compare the risk of congenital malformations (CMs) and prenatal outcomes of AEDs in infants/children who were exposed to AEDs in utero through a systematic review and Bayesian random-effects network meta-analysis. METHODS: MEDLINE, EMBASE, and Cochrane CENTRAL were searched from inception to December 15, 2015. Two reviewers independently screened titles/abstracts and full-text papers for experimental and observational studies comparing mono- or poly-therapy AEDs versus control (no AED exposure) or other AEDs, then abstracted data and appraised the risk of bias. The primary outcome was incidence of major CMs, overall and by specific type (cardiac malformations, hypospadias, cleft lip and/or palate, club foot, inguinal hernia, and undescended testes). RESULTS: After screening 5305 titles and abstracts, 642 potentially relevant full-text articles, and 17 studies from scanning reference lists, 96 studies were eligible (n = 58,461 patients). Across all major CMs, many AEDs were associated with higher risk compared to control. For major CMs, ethosuximide (OR, 3.04; 95% CrI, 1.23-7.07), valproate (OR, 2.93; 95% CrI, 2.36-3.69), topiramate (OR, 1.90; 95% CrI, 1.17-2.97), phenobarbital (OR, 1.83; 95% CrI, 1.35-2.47), phenytoin (OR, 1.67; 95% CrI, 1.30-2.17), carbamazepine (OR, 1.37; 95% CrI, 1.10-1.71), and 11 polytherapies were significantly more harmful than control, but lamotrigine (OR, 0.96; 95% CrI, 0.72-1.25) and levetiracetam (OR, 0.72; 95% CrI, 0.43-1.16) were not. CONCLUSION: The newer generation AEDs, lamotrigine and levetiracetam, were not associated with significant increased risks of CMs compared to control, and were significantly less likely to be associated with children experiencing cardiac malformations than control. However, this does not mean that these agents are not harmful to infants/children exposed in utero. Counselling is advised concerning teratogenic risks when the prescription is written for a woman of childbearing age and before women continue with these agents when considering pregnancy, such as switching from polytherapy to monotherapy with evidence of lower risk and avoiding AEDs, such as valproate, that are consistently associated with CMs. These decisions must be balanced against the need for seizure control. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42014008925.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-017-0845-1

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study flow
Fig. 1 Study flowCC BY · PubMed Central
Fig. 2 Rank heat plot for overall major congenital malformations (CMs), combined fetal losses, prenatal growth retardation, and preterm birth. Rank-heat plot of 49 treatments (presented in 49 radii) and four outcomes (presented in four concentric circles). Each sector is colored according to the SUCRA value of the corresponding treatment and outcome using the transformation of three colors: red (0%), yellow (50%), and green (100%). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 2 Rank heat plot for overall major congenital malformations (CMs), combined fetal losses, prenatal growth retardation, and preterm birth. Rank-heat plot of 49 treatments (presented in 49 radii) and four outcomes (presented in four concentric circles). Each sector is colored according to the SUCRA value of the corresponding treatment and outcome using the transformation of three colors: red (0%), yellow (50%), and green (100%). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central
Fig. 3 Network plots for overall major congenital malformations, combined fetal losses, prenatal growth retardation, and preterm birth. Each treatment node is weighted according to the number of patients that have received the particular treatment, and each edge is weighted according to the number of studies comparing the treatments it connects. carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 3 Network plots for overall major congenital malformations, combined fetal losses, prenatal growth retardation, and preterm birth. Each treatment node is weighted according to the number of patients that have received the particular treatment, and each edge is weighted according to the number of studies comparing the treatments it connects. carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central
Fig. 4 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Overall major congenital malformations (78 studies, 35,016 cases, 48 treatments). b Combined fetal losses (31 studies, 13,487 cases, 28 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 4 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Overall major congenital malformations (78 studies, 35,016 cases, 48 treatments). b Combined fetal losses (31 studies, 13,487 cases, 28 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central
Fig. 5 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Prenatal growth retardation (16 studies, 18,177 cases, 23 treatments). b Preterm birth (17 studies, 17,133 cases, 23 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 5 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Prenatal growth retardation (16 studies, 18,177 cases, 23 treatments). b Preterm birth (17 studies, 17,133 cases, 23 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central
Fig. 6 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Cardiac malformations (51 studies, 21,935 cases, 40 treatments). b Hypospadias (31 studies, 12,365 cases, 32 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 6 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Cardiac malformations (51 studies, 21,935 cases, 40 treatments). b Hypospadias (31 studies, 12,365 cases, 32 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central
Fig. 7 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Cleft lip/palate (29 studies, 18,987 cases, 33 treatments). b Club foot (23 studies, 8836 cases 27 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 7 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Cleft lip/palate (29 studies, 18,987 cases, 33 treatments). b Club foot (23 studies, 8836 cases 27 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central
Fig. 8 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Inguinal hernia (13 studies, 12,216 cases, 29 treatments). b Undescended testes (10 studies, 6270 cases, 17 treatments). c Minor congenital malformations (9 studies, 614 cases, 17 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrin
Fig. 8 Network meta-analysis forest plots for each treatment versus control. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects, and the red horizontal lines represent the corresponding predictive intervals (PrI). In the absence of heterogeneity, the CrIs and PrIs should be identical. An OR > 1 suggests that control is safer, whereas an OR < 1 suggests that the comparator active treatment is safer. The vertical blue line corresponds to an OR = 1 (i.e., the treatment groups compared are equally safe). The total sample size (n) included in each treatment is also presented. a Inguinal hernia (13 studies, 12,216 cases, 29 treatments). b Undescended testes (10 studies, 6270 cases, 17 treatments). c Minor congenital malformations (9 studies, 614 cases, 17 treatments). carbam carbamazepine, clobaz clobazam, clonaz clonazepam, ethos ethosuximide, gabap gabapentin, lamot lamotrigine, levet levetiracetam, oxcar oxcarbazepine, pheno phenobarbital, pheny phenytoin, primid primidone, topir topiramate, valpro valproate, vigab vigabatrinCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. Babic M, Jovic N. Postnatal concerns in children born to women with juvenile myoclonic epilepsy. In: European Congress on Epileptology, vol. 55. Stockholm: Epilepsia; 2014. p. 128.

Cited by

Sorted by citations

Items 201–300 of 339

Related

See all

Metadata

Authors
Veroniki, A. A., Cogo, E., Rios, P., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., Hemmelgarn, B. R., Yazdi, F., D’Souza, J., MacDonald, H., & Tricco, A. C.
Affiliations
  • St. Michael's Hospital (CA)
  • University of Toronto (CA)
  • University of Ottawa (CA)
  • University of Calgary (CA)
Corresponding author
Tricco, Andrea C.
ORCID
Venue
BMC Medicine
Publisher
Springer Science and Business Media LLC
Published
2017-05-05
Volume
15
Issue
1
Pages
95-95
ISSN
1741-7015 (ISSN-L)
DOI
10.1186/s12916-017-0845-1
PMC
PMC5418725
OpenAlex
W2611218072
Cited by
339
References
54
Citations by year
2026: 23 · 2025: 33 · 2024: 50 · 2023: 45 · 2022: 39 · 2021: 46 · 2020: 44 · 2019: 31 · 2018: 22 · 2017: 4
FWCI
5.17
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • TSpace (University of Toronto) (submittedVersion, cc-by)
  • Libraries and Cultural Resources (University of Calgary) (submittedVersion)
  • uO Research (University of Ottawa) (submittedVersion, public-domain)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Canadian Institutes of Health Research (Banting Postdoctoral Fellowship Program, New Investigator Award in Knowledge Synthesis)
  • Tier 1 Canada Research Chair in Knowledge Translation
  • Alberta Heritage Foundation for Medical Research (CA)
  • Tier 2 Canada Research Chair in Knowledge Synthesis
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Keywords
antiepileptic drugs, pregnancy, congenital malformations, prenatal outcomes, drug safety, epilepsy in pregnancy, valproic acid, ethosuximide, topiramate, phenytoin, carbamazepine, phenobarbital, lamotrigine, cardiac anomalies, hypospadias, cleft lip and palate, clubfoot
MeSH terms
Abnormalities, Drug-Induced, Network Meta-Analysis, Adult, Anticonvulsants, Bayes Theorem, Child, Epilepsy, Female, Humans, Infant, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review